Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
ovarian cancer (OC), Immune checkpoint association vs. anti-PD-(L)1, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results NRG GY003, 2020 0.79 [0.44; 1.42]
0.79 [0.44 ; 1.42 ] NRG GY003, 2020 1 0% 100 NA not evaluable progression or deaths (PFS)detailed results NRG GY003, 2020 0.53 [0.34; 0.82]
0.53 [0.34 ; 0.82 ] NRG GY003, 2020 1 0% 100 NA not evaluable objective responses (ORR)detailed results NRG GY003, 2020 3.28 [0.41; 26.42]
3.28 [0.41 ; 26.42 ] NRG GY003, 2020 1 0% 100 NA not evaluable AE (grade 3-4)detailed results NRG GY003, 2020 1.64 [0.74; 3.64]
1.64 [0.74 ; 3.64 ] NRG GY003, 2020 1 0% 100 NA not evaluable AE leading to death (grade 5)detailed results NRG GY003, 2020 2.18 [0.38; 12.47]
2.18 [0.38 ; 12.47 ] NRG GY003, 2020 1 0% 100 NA not evaluable TRAE (grade 3-4)detailed results NRG GY003, 2020 2.28 [1.01; 5.15]
2.28 [1.01 ; 5.15 ] NRG GY003, 2020 1 0% 100 NA not evaluable TRAE leading to death (grade 5)detailed results NRG GY003, 2020 1.04 [0.02; 53.53]
1.04 [0.02 ; 53.53 ] NRG GY003, 2020 1 0% 100 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results NRG GY003, 2020 2.10 [0.07; 64.18]
2.10 [0.07 ; 64.18 ] NRG GY003, 2020 1 0% 100 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results NRG GY003, 2020 2.10 [0.07; 64.18]
2.10 [0.07 ; 64.18 ] NRG GY003, 2020 1 0% 100 NA not evaluable Anaemia TRAE (grade 3-4)detailed results NRG GY003, 2020 4.44 [0.48; 41.25]
4.44 [0.48 ; 41.25 ] NRG GY003, 2020 1 0% 100 NA not evaluable Arthritis TRAE (grade 3-4)detailed results NRG GY003, 2020 2.10 [0.07; 64.18]
2.10 [0.07 ; 64.18 ] NRG GY003, 2020 1 0% 100 NA not evaluable Colitis TRAE (grade 3-4)detailed results NRG GY003, 2020 1.60 [0.26; 10.00]
1.60 [0.26 ; 10.00 ] NRG GY003, 2020 1 0% 100 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results NRG GY003, 2020 2.10 [0.07; 64.18]
2.10 [0.07 ; 64.18 ] NRG GY003, 2020 1 0% 100 NA not evaluable Fatigue TRAE (grade 3-4)detailed results NRG GY003, 2020 0.24 [0.03; 2.27]
0.24 [0.03 ; 2.27 ] NRG GY003, 2020 1 0% 100 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results NRG GY003, 2020 1.04 [0.02; 53.53]
1.04 [0.02 ; 53.53 ] NRG GY003, 2020 1 0% 100 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results NRG GY003, 2020 1.04 [0.02; 53.53]
1.04 [0.02 ; 53.53 ] NRG GY003, 2020 1 0% 100 NA not evaluable Nausea TRAE (grade 3-4)detailed results NRG GY003, 2020 0.52 [0.02; 15.72]
0.52 [0.02 ; 15.72 ] NRG GY003, 2020 1 0% 100 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results NRG GY003, 2020 2.13 [0.19; 24.25]
2.13 [0.19 ; 24.25 ] NRG GY003, 2020 1 0% 100 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results NRG GY003, 2020 2.10 [0.07; 64.18]
2.10 [0.07 ; 64.18 ] NRG GY003, 2020 1 0% 100 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results NRG GY003, 2020 1.04 [0.02; 53.53]
1.04 [0.02 ; 53.53 ] NRG GY003, 2020 1 0% 100 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results NRG GY003, 2020 1.04 [0.02; 53.53]
1.04 [0.02 ; 53.53 ] NRG GY003, 2020 1 0% 100 NA not evaluable Rash TRAE (grade 3-4)detailed results NRG GY003, 2020 1.04 [0.14; 7.71]
1.04 [0.14 ; 7.71 ] NRG GY003, 2020 1 0% 100 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results NRG GY003, 2020 6.59 [0.32; 135.04]
6.59 [0.32 ; 135.04 ] NRG GY003, 2020 1 0% 100 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 02:21 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 7,248,247,249,250,251,246
- treatments: 856,634,861,416,864,769,980